Solid Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Solid Biosciences Inc. (SLDB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.38 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 620.00K shares, a 0.00% change year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.76M shares, a 7848.18% increase year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.11M shares, a 1010.00% increase year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.75M shares, a 43.67% increase from fiscal 2024.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.22M shares, a 6.84% increase from fiscal 2023.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.14M shares, a 4.05% decline from fiscal 2022.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.19M shares, a 67.92% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 620.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.38M shares 10-Q · filed 2026-08-06 | 2.38M shares derived: sum of 3 quarters · filed 2026-08-06 | 3.49M shares derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | 1.76M shares 10-Q · filed 2026-05-12 | 1.76M shares derived: sum of 2 quarters · filed 2026-05-12 | 2.87M shares derived: sum of 3 quarters · filed 2026-05-12 | 3.49M shares derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 1.11M shares derived: sum of 2 quarters · filed 2026-03-19 | 1.73M shares derived: sum of 3 quarters · filed 2026-03-19 | 1.75M shares 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 1.11M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 1.73M shares derived: sum of 2 quarters · filed 2025-11-03 | 1.75M shares 10-Q · filed 2025-11-03 | 1.75M shares derived: sum of 4 quarters · filed 2025-11-03 | |||
| 2025-06-30 | 620.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 642.15K shares 10-Q · filed 2025-08-12 | 642.15K shares derived: sum of 3 quarters · filed 2025-08-12 | 742.15K shares derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2025-03-31 | 22.15K shares 10-Q · filed 2025-05-15 | 22.15K shares derived: sum of 2 quarters · filed 2025-05-15 | 122.15K shares derived: sum of 3 quarters · filed 2025-05-15 | ||||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 100.00K shares derived: sum of 2 quarters · filed 2025-03-06 | 1.22M shares 10-K · filed 2025-03-06 | ||||
| 2024-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 1.22M shares 10-Q · filed 2024-11-06 | |||||
| 2024-06-30 | 1.12M shares 10-Q · filed 2024-08-13 | ||||||
| 2023-12-31 | 1.14M shares 10-K · filed 2024-03-13 | ||||||
| 2022-12-31 | 886.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 887.80K shares derived: sum of 2 quarters · filed 2023-03-23 | 1.01M shares derived: sum of 3 quarters · filed 2023-08-14 | 1.19M shares 10-K · filed 2023-03-23 | |||
| 2022-09-30 | 1.44K shares 10-Q · filed 2022-11-10 | 128.61K shares derived: sum of 2 quarters · filed 2023-08-14 | 303.30K shares 10-Q · filed 2022-11-10 | 3.78M shares derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-06-30 | 127.17K shares 10-Q · filed 2023-08-14 | 1.91M shares 10-Q · filed 2022-08-11 | 301.90K shares 10-Q · filed 2023-08-14 | 4.53M shares 10-Q · filed 2022-08-11 | 3.78M shares derived: sum of 3 quarters · filed 2023-08-14 | 3.81M shares derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | 174.74K shares 10-Q · filed 2023-05-11 | 2.62M shares 10-Q · filed 2022-04-27 | 3.65M shares derived: sum of 2 quarters · filed 2023-05-11 | 3.68M shares derived: sum of 3 quarters · filed 2023-05-11 | 4.29M shares derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | 3.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | 3.51M shares derived: sum of 2 quarters · filed 2022-11-10 | 4.11M shares derived: sum of 3 quarters · filed 2022-11-10 | 3.71M shares 10-K · filed 2022-03-14 | |||
| 2021-09-30 | 30.55K shares 10-Q · filed 2022-11-10 | 458.35K shares 10-Q · filed 2021-11-03 | 634.95K shares derived: sum of 2 quarters · filed 2022-11-10 | 230.65K shares 10-Q · filed 2022-11-10 | 3.46M shares 10-Q · filed 2021-11-03 | ||
| 2021-06-30 | 604.40K shares 10-Q · filed 2022-08-11 | 3.00M shares 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | 2.40M shares 10-Q · filed 2022-04-27 | ||||||
| 2020-12-31 | 1.51M shares 10-K · filed 2021-03-15 | ||||||
| 2019-12-31 | 1.70M shares 10-K · filed 2020-03-12 | ||||||
| 2018-12-31 | 135.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | 427.02K shares derived: sum of 2 quarters · filed 2019-03-13 | 627.10K shares derived: sum of 3 quarters · filed 2019-03-13 | 1.19M shares 10-K · filed 2019-03-13 | |||
| 2018-09-30 | 291.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | 491.74K shares derived: sum of 2 quarters · filed 2018-11-13 | 1.05M shares 10-Q · filed 2018-11-13 | ||||
| 2018-06-30 | 200.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | 758.18K shares 10-Q · filed 2018-08-10 | |||||
| 2018-03-31 | 558.11K shares 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |